Get the Stockscreener App
11.98
12.11%
-1.65
After Hours:
12.04
0.06
+0.50%
Schrodinger Inc stock is traded at $11.98, with a volume of 5.28M.
It is down -12.11% in the last 24 hours and down -34.86% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$13.63
Open:
$13.57
24h Volume:
5.28M
Relative Volume:
4.80
Market Cap:
$882.50M
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-4.8898
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
-10.33%
1M Performance:
-34.86%
6M Performance:
-35.70%
1Y Performance:
-51.08%
1-Day Range:
$11.79
$13.74
1-Week Range:
$11.79
$13.94
52-Week Range:
$11.79
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, TEM, BTSG, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
11.98 | 1.00B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
177.04 | 30.74B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
53.61 | 9.94B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
BTSG
Brightspring Health Services Inc
|
40.06 | 7.10B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
76.92 | 6.69B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
25.96 | 5.03B | 550.17M | 201.35M | 232.07M | 1.00 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Neutral |
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-14-25 | Initiated | Barclays | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrodinger (NASDAQ:SDGR) Reaches New 12-Month LowWhat's Next? - MarketBeat
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25 - PharmiWeb.com
Schrodinger stock hits 52-week low at 12.8 USD - Investing.com
Schrodinger stock hits 52-week low at 12.8 USD By Investing.com - Investing.com India
Schrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Trading Systems Reacting to (SDGR) Volatility - Stock Traders Daily
With A 26% Price Drop For Schrödinger, Inc. (NASDAQ:SDGR) You'll Still Get What You Pay For - simplywall.st
Schrodinger stock hits 52-week low at 13.43 USD By Investing.com - Investing.com Nigeria
Schrodinger (NASDAQ:SDGR) Hits New 12-Month LowShould You Sell? - MarketBeat
Schrodinger stock hits 52-week low at 13.43 USD - Investing.com
Schrodinger, Inc. (SDGR) Investor Outlook: Unveiling a 77.43% Potential Upside Amidst Innovative Drug Discovery and Software Growth - DirectorsTalk Interviews
TruBridge (TBRG) Surges 5.6%: Is This an Indication of Further Gains? - Nasdaq
Analysts Are Bullish on Top Healthcare Stocks: Spectral AI (MDAI), Schrodinger (SDGR) - The Globe and Mail
Schrodinger (NASDAQ:SDGR) Upgraded at Wall Street Zen - MarketBeat
Is Schrödinger Inc. stock a good dividend stock2025 Historical Comparison & Weekly Stock Performance Updates - mfd.ru
Schrodinger, Inc. (SDGR) Investor Outlook: Unveiling a 60.98% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Schrodinger Inc stock hits 52-week low at $15.97 By Investing.com - Investing.com Nigeria
Schrodinger Inc stock hits 52-week low at $15.97 - Investing.com
How Schrodinger Inc. (SDGR) Affects Rotational Strategy Timing - Stock Traders Daily
Massachusetts Financial Services Co. MA Acquires 577,899 Shares of Schrodinger, Inc. $SDGR - MarketBeat
86,319 Shares in Schrodinger, Inc. $SDGR Acquired by Campbell & CO Investment Adviser LLC - MarketBeat
Stephens Investment Management Group LLC Trims Stock Holdings in Schrodinger, Inc. $SDGR - MarketBeat
Schrodinger (NASDAQ:SDGR) Shares Down 5.2%Time to Sell? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $91.37 Million Stock Holdings in Schrodinger, Inc. $SDGR - MarketBeat
(SDGR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Schrödinger Inc. stock could be next big winnerMarket Performance Report & Low Risk Entry Point Guides - Bộ Nội Vụ
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities By Investing.com - Investing.com South Africa
Assessing Schrödinger (SDGR) Valuation After Recent Uneven Share Price Momentum - Yahoo Finance
Schrödinger partners with Lilly TuneLab on AI drug discovery - Drug Target Review
Schrodinger stock rating reiterated at Buy by TD Cowen on strategic priorities - Investing.com Australia
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities - BioSpace
Schrödinger outlines 2026 priorities after strong 2025 By Investing.com - Investing.com Nigeria
Schrödinger outlines 2026 priorities after strong 2025 - Investing.com
Manas AI Secures Strategic Advantage through Unique Deep Integration with Schrödinger’s Physics + AI Discovery Platform - 01net
Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Chemoinformatics Market to Reach US$ 24.43 Billion by 2033 | CAGR - openPR.com
Schrodinger to offer Eli Lilly’s AI drug discovery platform on its software - WKZO
Will Schrödinger Inc. stock benefit from automation2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Schrodinger (NASDAQ:SDGR) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Schrödinger partners with Lilly TuneLab to enhance drug discovery By Investing.com - Investing.com Nigeria
Schrödinger, Inc.'s (NASDAQ:SDGR) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR? - simplywall.st
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign - pharmiweb.com
Schrödinger (SDGR) Partners with Eli Lilly for AI-Driven Drug Di - GuruFocus
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery - MSN
Schrödinger (SDGR) Partners with Eli Lilly for AI Drug Discovery - GuruFocus
Eli Lilly in pact with Schrödinger in AI-related drug discovery - Seeking Alpha
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):